Silverback Therapeutics (NASDAQ:SBTX) Stock Falls 3.5% – Should You Sell?

Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) dropped 3.5% on Friday. The company traded as low as $3.7950 and last traded at $3.81. 2,289,243 shares changed hands during trading, an increase of 577% from the average session volume of 337,931 shares. The stock had previously closed at $3.95.

Silverback Therapeutics Stock Performance

The company’s fifty day moving average price is $4.11 and its 200-day moving average price is $7.08. The stock has a market cap of $140.27 million, a P/E ratio of -1.61 and a beta of 0.60.

Silverback Therapeutics Company Profile

(Get Free Report)

Silverback Therapeutics was a clinical-stage biopharmaceutical company focused on developing medicines that direct immune-modulating therapies to diseased tissue. Its ImmunoTAC platform paired disease-targeting antibodies with therapeutic payloads intended to activate immune responses where needed. The company’s investigational programs included SBT6050, designed to target HER2-expressing tumors, and SBT6290, which targeted Nectin-4. These programs were being developed as potential treatments for cancer; they were investigational and had not been approved for commercial use.

Recommended Stories

Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.